Abstract: The present invention describes a second-generation tetanus toxoid vaccine and a process for the preparation thereof, comprising the steps of: inducing an E. Coli culture OD 600=0.5 by adding 0.2 mM IPTG; growing the culture at 14-16° C. for 14 to 20 hours; suspending the culture in 25 mM phosphate buffer containing 200 mM sodium chloride; adding 1% of triton-X-100 to the phosphate buffer, and adding the buffer to the culture; sonicating the culture for a period of 3 minutes (at 5 sec on/off pulse) at 4° C. on cold beads; centrifuging the culture for 60 to 90 minutes; collecting and purifying a supernatant using Ni-NTA affinity column with an eluant; and combining the supernatant into a pool with contaminated bands and concentrating using Centriprep-30 centrifuge filters (30 kDa pores).

Abstract: Compositions comprising the L complex or the M complex of the botulinum neurotoxin E with its associated neurotoxin binding protein(s) (NBP), methods of making, and methods of use to treat pain and wrinkles by injecting locally. Methods of making and isolating the L and M complex comprise a multi-step process of: providing a bacterial cultured media comprising the complex of botulinum neurotoxin E and neurotoxin binding proteins; centrifuging and pelletizing the cultured media; stirring the pelletized culture at 0 to 10° C. over a period of 4 to 24 hours; centrifuging the stirred solution to obtain a supernatant; precipitating the supernatant and filtering to obtain the precipitate; and dissolving the precipitate, centrifuging and filtering to obtain a solution comprising M complex and/or L complex of botulinum neurotoxin E and its NBP; and passing the solution through a functionalized sephadex ion exchange column to isolate the complex.

Abstract: Methods and server systems for computing fraud risk scores for various merchants associated with an acquirer described herein. The method performed by a server system includes accessing merchant-related transaction data including merchant-related transaction indicators associated with a merchant from a transaction database. Method includes generating a merchant-related transaction features based on the merchant-related indicators. Method includes generating via risk prediction models, for a payment transaction with the merchant, merchant health and compliance risk scores, merchant terminal risk scores, merchant chargeback risk scores, and merchant activity risk scores based on the merchant-related transaction features. Method includes facilitating transmission of a notification message to an acquirer server associated with the merchant.

Abstract: Techniques for multi-stream transactional event processing under ACID semantics in a distributed log-based append-only datastore are described. A transaction coordinator writes events that are part of a transaction to a transaction buffer, where the events can be made visible to clients involved in the transaction while other clients are not aware. Upon committing the transaction, an optimistic concurrency control based technique is utilized to attempt to obtain locks on all events involved in the transaction across one or multiple shards by one or multiple designated writer nodes. When all involved writer nodes indicate that they are able to commit their events, the transaction can be committed.

Abstract: In one aspect, an example methodology implementing the disclosed techniques includes, by an order prioritization service, receiving information regarding orders that need to be fulfilled and determining, for each one of the orders, one or more relevant features from the information regarding the order, the one or more relevant features influencing prediction of an order priority. The method also includes, by the order prioritization service, predicting, using a machine learning (ML) model, a priority score for each one of the orders based on the determined one or more relevant features, and ranking the orders based on their respective priority scores.

Abstract: The present invention describes a neurotoxin associated protein from botulinum neurotoxin complex used as an oral or nasal delivery system for a vaccine. The vaccine is selected from tetanus, diphtheria and pertussis alone or in combination. Further the oral or nasal delivery of tetanus vaccine in combination with other drug molecules.

Abstract: A recombinant SARS-CoV2 protein-based vaccine, and method of immunizing, is developed by either embedding the epitopes/domains, or chemically attaching, to an already established vaccine candidate, such as a detoxified recombinant tetanus neurotoxin (DrTeNT), to develop a novel vaccine to immunize against SARS-CoV2. The developed vaccine will have three novel contributions compared to the present vaccine technology; a) providing a novel and very effective vaccine platform; b) priming with DrTeNT will prepare the host immune system for better response; and c) oral delivery of the vaccine candidate with a group of neurotoxin binding proteins (NAPs) from Clostridium sp. A Detoxified recombinant tetanus neurotoxin (DrTeNT) is prepared by mutation of the active site amino acid residues is an effective vaccine candidate, and is to be used for embedding epitopes of SARS-CoV-2 virus protein for vaccination against Covid-19. DrTeNT is a risk-free vaccine, free of formalin or any other chemical adjuvants.

Abstract: An example methodology implementing the disclosed techniques includes receiving a parts configuration specified for a product and generating a first feature vector that represents features from the product. The method also includes predicting, using a trained quote-time issue prediction module, whether the parts configuration specified for the product will or will not result in issues based on the first feature vector and, responsive to a prediction that the parts configuration specified for the product will not result in issues, accepting an order for the product. The method may further include receiving manufacturing details selected for the product, generating a second feature vector that represents features from the product and the selected manufacturing details, and predicting, using a trained manufacture-time issue prediction module, whether producing the product in accordance with the selected manufacturing details will or will not result in issues based on the second feature vector.

Abstract: The present invention provides a method for detecting and assaying Clostridium neurotoxins and identification of serotypes of botulinum neurotoxins in various food matrices and clinical samples. This method is also used for detection of BoNT inside the neuronal and epithelial cells. The method comprises detecting and assaying the presence of a Clostridium neurotoxin in a sample by: exposing the sample containing a Clostridium neurotoxin to a sample comprising a novel SNAMPXIN/SNAMP universal recombinant substrate fusion protein capable of producing a detectable FRET, following cleavage; detecting and assaying the presence of the Clostridium neurotoxin by measuring a change in the energy transfer or the luminescence signal; and detecting and assaying an electrophoretic mobility pattern of one or more cleaved protein bands or a degraded protein, using a high throughput automated system to identify the different serotypes of the Clostridium neurotoxin.

Abstract: In one aspect, an example methodology implementing the disclosed techniques includes receiving a corpus of historical order fulfillment data regarding a plurality of completed orders for one or more products, the historical order fulfillment data including an actual delivery time for each product in a completed order, and identifying, from the corpus of historical order fulfillment data, a plurality of features for a product, the plurality of features correlated with an actual delivery time for the product. The method also includes generating a training dataset using the identified plurality of features, the training dataset including a plurality of training samples, each training sample of the plurality of training samples corresponding to a product and including one or more identified features and the actual delivery time for the product. The method may include training the delivery time prediction module using the plurality of training samples.

Abstract: Compositions comprising the L complex or the M complex of the botulinum neurotoxin E with its associated neurotoxin binding protein(s) (NBP), methods of making, and methods of use to treat pain and wrinkles by injecting locally. Methods of making and isolating the L and M complex comprise a multi-step process of: providing a bacterial cultured media comprising the complex of botulinum neurotoxin E and neurotoxin binding proteins; centrifuging and pelletizing the cultured media; stirring the pelletized culture at 0 to 10° C. over a period of 4 to 24 hours; centrifuging the stirred solution to obtain a supernatant; precipitating the supernatant and filtering to obtain the precipitate; and dissolving the precipitate, centrifuging and filtering to obtain a solution comprising M complex and/or L complex of botulinum neurotoxin E and its NBP; and passing the solution through a functionalized sephadex ion exchange column to isolate the complex.

Abstract: A cleaning and disinfecting composition comprises a long-chain alkyl polyamine, such as dodecyl dipropylene triamine; a long-chain quaternary ammonium salt, such as N,N-didecyl-N,N-dimethylammonium chloride; and a metal carbonate salt, such as potassium carbonate, all in aqueous solution. A sequestering agent, a long-chain alkyl polyethoxylate, an alkanolamine and an anti-corrosive agent may also be present. The composition has a pH at least 11 when diluted to an in-use concentration. It may be used to clean and disinfect hard surfaces, such as medical, dental and surgical implements, walls, floors, sinks and hard furnishing surfaces, or soft surfaces such as bedding, upholstery or clothing. The composition is effective as a virucide, a sporicide, a bacteriocide, a fungicide, and against yeasts and moulds, without harming the substrate cleansed.

Abstract: The present invention relates to a method of treating an individual suffering from botulism comprising administering to the individual a composition comprising a therapeutically effective amount of Compound 1 or its pharmaceutically acceptable salts or derivatives thereof.

Abstract: Presently claimed invention related to a pharmaceutical composition comprising ascorbic acid caffeoylquinic acid, rosmarinic acid. and glycosyl sulfones obtained from Ocimum Sanctum and a process for isolating said composition from Ocimum Sanctum. Presently claimed invention also provides a method of treating neural crest derived tumors such as malignant neurofibroma and melanoma.

Abstract: A cleaning and disinfecting composition comprises a long-chain alkyl polyamine, such as dodecyl dipropylene triamine; a long-chain quaternary ammonium salt, such as N,N-didecyl-N,N-dimethylammonium chloride; and a metal carbonate salt, such as potassium carbonate, all in aqueous solution. A sequestering agent, a long-chain alkyl polyethoxylate, an alkanolamine and an anti-corrosive agent may also be present. The composition has a pH of at least 11 when diluted to an in-use concentration, and may be used to clean and disinfect hard surfaces, such as medical, dental and surgical implements, walls, floors, sinks and hard furnishing surfaces, or soft surfaces such as bedding, upholstery or clothing. The composition is effective as a virucide, a sporicide, a bacteriocide, a fungicide, and against yeasts and moulds, without harming the substrate cleansed.

Abstract: The present invention provides an improved process for the preparation of halogenated benzylamine having the formula I from halogenated benzonitriles, Formula I wherein, X1 is selected from group consisting of hydrogen, chloro or fluoro, provided at least one X1 is chloro or fluoro.

Abstract: Present invention relates to a pharmaceutical composition comprising P80 with drugs, dyes, small molecules, biomolecules, proteins or combination thereof. P80 enhances the transportation of molecules associated with it. The P80 is a tight junction modulators to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery. The invention further provides a process for the preparation, isolation and purification of p80 protein.

Abstract: The main aspect of present invention is to provide a pharmaceutical composition to increase the stability of liquid formulation of botulinum toxin and related proteins. The present invention provides a method to stabilize toxin in liquid formulation. Lipid based drug delivery system is known to increase the bioavailability of drugs (Amidon et al., 1995; Jannin et al., 2008). We investigated the stability of BoNT/A toxin and complex. We used two formulations in liquid phase: combination of lipids and liposomes, with two different storage conditions: 4° C. and 25° C. The present invention also provides a method for efficient delivery of botulinum toxin through skin as a topical application.

Abstract: Present invention provides a stable pharmaceutical composition comprising botulinum neurotoxin, anesthetic in a buffer. Present invention also provides a process for the preparation of the stable pharmaceutical composition. The botulinum neurotoxin is stabilized by the formation of complex between the toxin and anesthetic. The present invention further provides a method for treating wrinkles using the said pharmaceutical composition.

Abstract: The present invention relates to a composition for the delivery of drug molecules, especially therapeutic proteins via oral route, sublingual, and buccal routes. The embodiments herein provide delivery of therapeutic proteins with the help of neurotoxin associated proteins (NAPs) from Clostridium botulinum type A or type E. The NAPs combine with proteins and/or drug molecules to form a composition for oral or sublingual delivery.